

November 11, 2024

To, <b>BSE Limited</b> , 25, P. J. Towers, Dalal Street, Mumbai – 400 001 <b>Ref: Company Scrip Code: 532834</b>	To, Listing Department, <b>National Stock Exchange of India Ltd.</b> , Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 <b>Ref: Symbol: CAMLINFINE    Series: EQ</b>
---	--

**Sub: Outcome of the Board Meeting: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“Listing Regulations”) (read with Schedule III).**

Dear Sir/Madam,

This is to inform you that the Board of Directors, at its meeting held today i.e. Monday, November 11, 2024, inter alia, approved the following:

**1. Financial Statements / Results:**

This has reference to our intimation dated October 28, 2024.

The Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2024. A copy of the said Results along with the Limited Review Reports issued by the Statutory Auditors are enclosed herewith as Annexure 1. The said Results shall be published in newspapers as per the Listing Regulations.

**2. Liquidation of CFS Pahang Asia Pte Ltd., Subsidiary Company of the Company:**

The Board has approved the liquidation of CFS Pahang Asia Pte Ltd., Subsidiary Company of the Company. It may be noted that CFS Pahang Asia Pte Ltd is not a material subsidiary of the Company and therefore it will not impact materially on consolidated financials of the Company.

Disclosure under Regulation 30 read with Part A of Schedule III of Listing Regulations read along with SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed as Annexure 2.

**3. Appointment of Mr. Saurabh Upadhyay as General Manager - Food Division designated as Senior Management Personnel:**

Based on the recommendation of Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Saurabh Upadhyay as General Manager - Food Division designated as Senior Management Personnel who shall join the Company tentatively on or before November 28, 2024.

Disclosure under Regulation 30 read with Part A of Schedule III of Listing Regulations read along with SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed as Annexure 3.



**Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLCO75361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

The above information is also available on the Company's Website (<https://www.camlinfs.com/>).

The Board meeting commenced at 01:00 p.m. (IST) and concluded at 03:15 p.m. (IST).

This is for your information and record please.

Encl.: a/a.

Thanking You,

**For Camlin Fine Sciences Limited**

**Rahul Sawale**  
**Company Secretary**  
**& VP - Legal**

 **Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLCO75361

 +91 22 6700 1000

 +91 22 2832 4404

 [corporate@camlinfs.com](mailto:corporate@camlinfs.com)

 [www.camlinfs.com](http://www.camlinfs.com)

CAMLIN FINE SCIENCES LIMITED  
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024

(Rs.in Lakh, except per share data)

	PARTICULARS	STANDALONE						CONSOLIDATED					
		QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	22,691.18	18,191.22	20,621.41	40,882.40	36,732.57	77,326.21	42,297.15	39,585.33	40,587.94	81,882.48	82,548.20	161,306.20
2	Other income	308.13	178.01	563.42	486.14	1,120.47	1,888.26	1,209.69	186.76	176.09	369.20	812.84	1,555.64
3	<b>Total income</b>	<b>22,999.31</b>	<b>18,369.23</b>	<b>21,184.83</b>	<b>41,368.54</b>	<b>37,853.04</b>	<b>79,214.47</b>	<b>43,506.84</b>	<b>39,772.09</b>	<b>40,764.03</b>	<b>82,251.68</b>	<b>83,361.04</b>	<b>162,861.84</b>
4	<b>Expenses</b>												
	Cost of materials consumed	15,105.32	13,169.71	11,348.70	28,275.03	21,424.23	42,628.92	22,306.05	21,454.27	20,618.40	43,760.32	45,374.55	74,661.46
	Purchase of stock in trade	1,362.71	226.12	264.92	1,588.83	355.69	845.85	5,392.86	1,584.26	1,225.70	6,977.12	3,192.83	11,425.87
	Changes in inventories of finished goods/WIP/stock in trade	(3,405.54)	(3,196.39)	(831.29)	(6,601.93)	(4,675.92)	891.99	(5,791.54)	(1,235.01)	516.85	(7,026.55)	(4,628.39)	5,274.78
	Employee benefits expense	1,959.58	1,681.32	1,769.95	3,640.90	3,318.04	6,594.84	5,227.52	5,117.79	4,324.17	10,345.31	8,709.02	17,874.77
	Finance costs	1,791.76	1,361.73	1,510.20	3,153.49	2,714.89	5,432.60	2,642.13	2,337.43	1,977.79	4,979.56	2,999.79	6,030.49
	Depreciation and amortisation expense	1,343.64	1,269.32	1,240.93	2,612.96	2,420.64	4,939.00	2,069.14	2,011.15	1,920.08	4,080.29	3,798.11	7,860.61
	Other expenses	6,268.75	5,617.11	5,933.76	11,885.86	11,621.59	23,651.67	10,837.99	10,850.26	11,389.54	20,661.00	23,515.91	44,677.81
	<b>Total Expenses</b>	<b>24,426.22</b>	<b>20,128.92</b>	<b>21,237.17</b>	<b>44,555.14</b>	<b>37,179.16</b>	<b>84,984.87</b>	<b>42,664.15</b>	<b>42,120.15</b>	<b>41,972.53</b>	<b>83,777.05</b>	<b>82,961.82</b>	<b>167,805.79</b>
5	<b>Profit / (Loss) before exceptional items and share of profit / (loss) of associate (3-4)</b>	<b>(1,426.91)</b>	<b>(1,759.69)</b>	<b>(52.34)</b>	<b>(3,186.60)</b>	<b>673.88</b>	<b>(5,770.40)</b>	<b>822.69</b>	<b>(2,348.06)</b>	<b>(1,208.50)</b>	<b>(1,525.37)</b>	<b>399.22</b>	<b>(4,943.95)</b>
6	Exceptional items (Refer Note 7)	9,626.66	-	-	9,626.66	-	192.84	15,103.90	-	-	15,103.90	-	4,980.40
7	<b>Profit / (Loss) before share of profit / (loss) of associate (5-6)</b>	<b>(11,053.57)</b>	<b>(1,759.69)</b>	<b>(52.34)</b>	<b>(12,813.26)</b>	<b>673.88</b>	<b>(5,963.24)</b>	<b>(14,281.21)</b>	<b>(2,348.06)</b>	<b>(1,208.50)</b>	<b>(16,629.27)</b>	<b>399.22</b>	<b>(9,924.35)</b>
8	Share of profit / (loss) of associate	-	-	-	-	-	-	50.50	-	-	50.50	-	-
9	<b>Profit / (Loss) before tax (7-8)</b>	<b>(11,053.57)</b>	<b>(1,759.69)</b>	<b>(52.34)</b>	<b>(12,813.26)</b>	<b>673.88</b>	<b>(5,963.24)</b>	<b>(14,230.71)</b>	<b>(2,348.06)</b>	<b>(1,208.50)</b>	<b>(16,578.77)</b>	<b>399.22</b>	<b>(9,924.35)</b>
10	<b>Tax Expenses</b>												
	- Current tax (Refer Note 8)	544.25	(378.28)	19.61	165.97	195.93	-	1,641.48	739.88	785.91	2,381.36	1,187.47	2,487.23
	- Deferred tax	(4,335.66)	(13.40)	73.61	(4,349.06)	45.47	(824.32)	(4,261.41)	377.08	88.53	(3,884.33)	93.02	(1,924.07)
		(3,791.41)	(391.68)	93.22	(4,183.09)	241.40	(824.32)	(2,619.93)	1,116.96	874.44	(1,502.97)	1,280.49	563.16
11	<b>Profit / (Loss) for the period (9-10)</b>	<b>(7,262.16)</b>	<b>(1,368.01)</b>	<b>(145.56)</b>	<b>(8,630.17)</b>	<b>432.48</b>	<b>(5,138.92)</b>	<b>(11,610.78)</b>	<b>(3,465.02)</b>	<b>(2,082.94)</b>	<b>(15,075.80)</b>	<b>(881.27)</b>	<b>(10,487.51)</b>
12	<b>Other comprehensive income</b>												
A	<b>Items that will not be reclassified to profit or loss</b>												
(i)	Remeasurements of defined benefit plans	(23.79)	(15.57)	(4.54)	(39.36)	(15.19)	(8.54)	(23.79)	(15.57)	(4.54)	(39.36)	(15.19)	(9.07)
(ii)	Income tax relating to items that will not be reclassified to profit or loss	8.31	5.44	1.59	13.75	5.31	2.98	8.31	5.44	1.59	13.75	5.31	2.98
B	<b>Items that will be reclassified to profit or loss</b>												
(i)	Exchange differences on translating the financial statements of foreign operations	-	-	-	-	-	-	74.08	(650.17)	(143.42)	(576.09)	223.05	1,801.40
(ii)	The effective portion of gain or loss on hedging instruments in a cash flow hedge	(86.16)	100.58	(163.09)	14.42	48.88	1.70	(86.16)	100.58	(163.09)	14.42	48.88	1.70
(iii)	Income tax relating to items that will be reclassified to profit or loss	30.11	(35.15)	61.86	(5.04)	(12.21)	(0.60)	30.11	(35.15)	61.86	(5.04)	(12.21)	(0.60)
	<b>Other comprehensive income</b>	<b>(71.53)</b>	<b>55.30</b>	<b>(104.18)</b>	<b>(16.23)</b>	<b>26.79</b>	<b>(4.46)</b>	<b>2.55</b>	<b>(594.87)</b>	<b>(247.60)</b>	<b>(592.32)</b>	<b>249.84</b>	<b>1,796.41</b>
13	<b>Total comprehensive income for the period (11+12)</b>	<b>(7,333.69)</b>	<b>(1,312.71)</b>	<b>(249.74)</b>	<b>(8,646.40)</b>	<b>459.27</b>	<b>(5,143.38)</b>	<b>(11,608.23)</b>	<b>(4,059.89)</b>	<b>(2,330.54)</b>	<b>(15,668.12)</b>	<b>(631.43)</b>	<b>(8,691.10)</b>
14	<b>Profit / (Loss) attributable to:</b>												
(i)	Owners of the Company							(10,023.16)	(3,395.41)	(1,938.30)	(13,418.57)	(382.84)	(9,275.34)
(ii)	Non-controlling interests							(1,587.62)	(69.61)	(144.64)	(1,657.23)	(498.43)	(1,212.17)
15	<b>Other comprehensive income attributable to:</b>												
(i)	Owners of the Company							24.30	(645.93)	(251.22)	(621.63)	298.13	1,835.36
(ii)	Non-controlling interests							(21.75)	51.06	3.62	29.31	(48.29)	(38.95)
16	<b>Total comprehensive income attributable to:</b>												
(i)	Owners of the Company							(9,998.86)	(4,041.34)	(2,189.52)	(14,040.20)	(84.71)	(7,439.98)
(ii)	Non-controlling interests							(1,609.37)	(18.55)	(141.02)	(1,627.92)	(546.72)	(1,251.12)
17	Paid-up Equity Share Capital (Face Value Re.1/- per share)	1,674.95	1,674.95	1,674.55	1,674.95	1,674.55	1,674.65	1,674.95	1,674.95	1,674.55	1,674.95	1,674.55	1,674.65
18	Other Equity				61,297.34	75,493.68	69,896.75				67,301.82	92,628.44	84,800.43
19	Earnings per Share (EPS) (of Re.1/-each) (not annualised)												
	Basic (Rs.)	(4.34)	(0.82)	(0.09)	(5.15)	0.26	(3.09)	(5.98)	(2.03)	(1.17)	(8.01)	(0.23)	(5.58)
	Diluted (Rs.)	(4.29)	(0.81)	(0.09)	(5.10)	0.26	(3.05)	(5.93)	(2.01)	(1.16)	(7.94)	(0.23)	(5.50)

+91 22 6700 1000



+91 22 2832 4404




corporate@camlinfs.com



www.camlinfs.com

Registered Office:  
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 099  
CIN: L74100MH1993PLC075361



ANNEXURE-1

**Notes to Unaudited Financial Results:**

- The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 11, 2024. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India. The Statutory Auditors of the Company have carried out Limited Review of these financial results.
- Other income / Other expense above includes net foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE						CONSOLIDATED						Rs. In Lakh
	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED	
	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
Exchange gain	181.16	15.83	434.60	196.99	390.38	541.51	1,044.06	-	-	16.81	-	-	
Exchange loss	-	-	-	-	-	-	-	1,027.25	654.14	-	1,252.43	3,946.68	
<b>Total Exchange gain / (loss)</b>	<b>181.16</b>	<b>15.83</b>	<b>434.60</b>	<b>196.99</b>	<b>390.38</b>	<b>541.51</b>	<b>1,044.06</b>	<b>(1,027.25)</b>	<b>(654.14)</b>	<b>16.81</b>	<b>(1,252.43)</b>	<b>(3,946.68)</b>	

The exchange gain / (loss) shown above excludes exchange gain / (loss) on derivative contracts accounted as cash flow hedge.

- Finance costs include foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE						CONSOLIDATED						Rs. In Lakh
	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED	
	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
Exchange gain	-	-	-	-	-	-	-	-	-	-	143.86	419.58	
Exchange loss	113.44	20.04	263.46	133.48	125.89	168.78	524.66	636.94	472.42	1,161.60	-	-	
<b>Total Exchange gain / (loss)</b>	<b>(113.44)</b>	<b>(20.04)</b>	<b>(263.46)</b>	<b>(133.48)</b>	<b>(125.89)</b>	<b>(168.78)</b>	<b>(524.66)</b>	<b>(636.94)</b>	<b>(472.42)</b>	<b>(1,161.60)</b>	<b>143.86</b>	<b>419.58</b>	

- During the quarter ended September 30, 2024, the Company has not allotted any shares under Employees Stock Option Scheme, 2018 (ESOP-2018) and Employees Stock Option Scheme, 2020 (ESOP-2020). 1400 employee stock options have lapsed under ESOP-2018 during the quarter ended September 30, 2024. No employee stock options have lapsed under ESOP-2020 during the quarter ended September 30, 2024.

- The Board of Directors of the Company and the Shareholders at their respective meetings held on September 10, 2024 and October 18, 2024, approved the increase in Authorised Capital of the Company to Rs. 21,50,00,000/- (21,50,00,000 equity shares of Re. 1/- each) from Rs. 18,00,00,000/- (18,00,00,000 equity shares of Re. 1/- each).

- On June 11, 2024, wholly owned subsidiary of the company, Dresen Quimica SAPI De CV, Mexico, has acquired entire stake in Vitafor Invest NV, Belgium at a consideration of Euro 1. Vitafor Invest NV has wholly owned subsidiaries/associate namely Addi-Tech NV (100%); Vitafor NV (100%); Vitafor China Ltd. (100%); Europe Bio Engineering BV (100%) and Vial Sàrl (45%) (collectively known and referred as "Vitafor Group"). The consolidated financial statements include the unaudited results of Vitafor Group for the period June 11, 2024, to September 30, 2024.

**Note on Exceptional Items**

- Based on an extensive review carried out during the quarter of the present economic situation in Europe, Management of the Company is of the view that there are likely inordinate delays in the revival and / or repurposing of the Diphenol facility of wholly owned subsidiary CFS Europe SpA, Italy (CFS Europe) to make it commercially viable in the foreseeable future. In this situation, the Management has decided to continue with the Blending business in Italy and to explore an alternate plan for utilisation of the facility including a negotiated settlement with its lenders. Under these circumstances, Management has regarded it prudent to make a provision for impairment of the Cash Generating Unit (CGU) relating to Diphenol facility of CFS Europe in the results for the current quarter.
- A similar exhaustive review was carried out, during the quarter, by the Management of the operations of its subsidiary CFS Wanglong Flavors (Ningbo) Co. Ltd. (CPSWL), China. The present global economic conditions including those in China, have rendered the repurposing of the facility owned by CFSWL economically unviable. Pursuant to this, the management has recognised an impairment provision of the investment, receivables and assets of CFSWL in the results for the current quarter.
- Management of the Company has decided to dissolve its subsidiary CFS Pahang Asia Pte Ltd, pursuant to which an impairment provision for the entire value of the investment in that subsidiary has been recognised in the results for the current quarter.
- Company has demolished/scrapped certain assets, which were located in India including those owned by subsidiary Chemolutions Chemicals Limited, for refurbishing them for alternate use. The loss arising from this action has also been provided in the results for the current quarter.
- Group has recognised acquisition related costs for its investment in Vitafor Invest NV, Belgium in the results of the current quarter.

Accordingly, the exceptional items, expense (net) recognised in Profit and Loss in the current quarter include:

**I. In the standalone financial results:**

- Impairment loss on investments in subsidiaries namely:
  - CFS Europe Rs. 1,178.56 Lakh
  - CPSWL Rs. 436.92 Lakh ( Previous year ended 31.03.2024 Rs. 192.84 Lakh)
  - CFS Pahang Asia Pte Ltd Rs. 17.90 Lakh
- Impairment of trade and other receivables (net of payables) due from subsidiaries:
  - CFS Europe SpA Rs. 1,929.04 Lakh
  - CPSWL Rs. 5,886.89 Lakh
- Loss on demolition / refurbishment of assets Rs. 177.35 Lakh

**II. In the consolidated financial results:**

- Impairment of Property Plant and Equipment, Intangibles and certain other assets:
  - Relating to CGU of Diphenol facility at CFS Europe SpA Rs. 11,649.14 Lakh (Net of adjustment to Revaluation Reserve Rs. 3,499.23 Lakh) ( Previous year ended 31.03.2024 Inventory write off Rs. 2,279.56 Lakh)
  - Relating to CPSWL Rs. 1,875.24 Lakh ( Previous year ended 31.03.2024 Rs. 2,700.84 Lakh)
  - Derecognition of deferred taxes of CFSWL Rs. 1,157.40 Lakh
- Acquisition related costs of Vitafor Group Rs. 201.72 Lakh
- Loss on demolition / refurbishment of assets Rs. 220.39 Lakh



**Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLC075361

+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com



For Camlin Fine Sciences Limited

*Ashish S. Dandekar*  
Ashish S. Dandekar  
Chairman & Managing Director  
DIN: 01077379

8 Current Tax for the quarter and half year ended September 30, 2024 includes tax provision relating to earlier years amounting to Rs. 165.97 Lakh.  
9 Operational Revenue and Operational loss before tax of CFS Europe considered in consolidated results for the quarter September 30, 2024 is as under:

Particulars	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Revenue	1,883.65	3,008.40	4,223.83	4,892.05	15,462.67	22,705.26
Loss before tax	(1,366.91)	(1,508.15)	(2,644.64)	(2,875.05)	(3,001.37)	(10,736.27)

No deferred tax has been recognised on the loss for the quarter ended September 2024.

10 The Company's operations constitute a single business segment in Speciality Chemicals.

Place: Mumbai  
Date: November 11, 2024



**Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLC075361

+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

**CAMLIN FINE SCIENCES LIMITED**  
BALANCE SHEET AS AT SEPTEMBER 30, 2024

(Rs.in Lakh)

	PARTICULARS	STANDALONE		CONSOLIDATED	
		30.09.2024 (Unaudited)	31.03.2024 (Audited)	30.09.2024 (Unaudited)	31.03.2024 (Audited)
	<b>ASSETS</b>				
	<b>Non-Current Assets</b>				
(1)	(a) Property, Plant and Equipment	51,553.18	52,327.70	58,269.71	71,224.24
	(b) Capital work-in-progress	2,416.85	3,126.13	2,243.16	4,556.45
	(c) Right-Of-Use Assets	3,536.67	3,665.92	4,424.04	4,452.13
	(d) Goodwill	-	-	7,608.49	4,707.66
	(e) Intangible Assets	1,547.55	1,658.52	1,279.60	1,250.75
	(f) Intangible Assets under development	-	17.85	478.52	30.51
	(g) <b>Financial Assets</b>				
	(i) Investments	6,353.39	7,986.77	2,345.39	787.58
	(ii) Loans	-	469.06	-	-
	(iii) Other financial assets	377.25	323.83	1,486.48	1,387.79
	(h) Deferred tax assets (net)	3,674.07	-	6,154.90	4,050.32
	(i) Income tax assets	663.80	1,079.37	1,590.93	2,117.52
	(j) Other non-current assets	472.35	494.01	514.16	540.75
	<b>Total Non-current Assets</b>	<b>70,595.11</b>	<b>71,149.16</b>	<b>86,395.38</b>	<b>95,105.70</b>
(2)	<b>Current Assets</b>				
	(a) Inventories	25,168.71	25,491.25	50,120.78	51,270.41
	(b) <b>Financial assets</b>				
	(i) Trade receivables	37,344.39	49,181.14	30,944.01	28,515.16
	(ii) Cash and cash equivalents	23.37	67.70	7,949.50	8,025.47
	(iii) Other bank balances	1,109.47	1,327.79	1,109.47	1,327.79
	(iv) Loans	5,741.40	5,202.31	233.10	1,006.13
	(v) Other financial assets	2,906.07	2,437.80	1,216.23	180.93
	(c) Other current assets	2,524.58	2,135.05	10,340.86	9,533.62
	<b>Total Current Assets</b>	<b>74,817.99</b>	<b>85,843.04</b>	<b>101,913.95</b>	<b>99,859.51</b>
	(d) Asset held for sale	207.19	207.19	207.19	207.19
	<b>TOTAL ASSETS</b>	<b>145,620.29</b>	<b>157,199.39</b>	<b>188,516.52</b>	<b>195,172.40</b>
	<b>EQUITY AND LIABILITIES</b>				
	<b>EQUITY</b>				
(1)	(a) Equity Share Capital	1,674.95	1,674.65	1,674.95	1,674.65
	(b) Other Equity	61,297.34	69,896.75	67,301.82	84,800.43
	(c) Non-Controlling Interest	-	-	(2,446.84)	(780.04)
	<b>Total Equity</b>	<b>62,972.29</b>	<b>71,571.40</b>	<b>66,529.93</b>	<b>85,695.04</b>
	<b>LIABILITIES</b>				
	<b>Non-current Liabilities</b>				
(2)	(a) <b>Financial Liabilities</b>				
	(i) Borrowings	19,543.48	22,230.80	34,055.17	33,271.85
	(ii) Lease liabilities	1,275.79	1,470.94	1,913.08	1,715.99
	(iii) Other financial liabilities	-	-	34.44	33.05
	(b) Provisions	543.84	496.64	559.18	510.63
	(c) Deferred tax liabilities (net)	-	683.74	335.31	683.70
	(d) Other non-current liabilities	-	-	32.71	34.66
	<b>Total Non-Current Liabilities</b>	<b>21,363.11</b>	<b>24,882.12</b>	<b>36,929.89</b>	<b>36,249.88</b>
(3)	<b>Current Liabilities</b>				
	(a) <b>Financial Liabilities</b>				
	(i) Borrowings	31,283.16	26,931.59	39,893.77	32,493.91
	(ia) Lease liabilities	585.16	504.04	826.76	821.39
	(ii) Trade Payables				
	(A) Total outstanding dues of micro enterprises and small enterprises; and	4,799.22	3,878.27	4,799.22	3,878.27
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	17,754.26	24,542.44	29,078.16	28,585.64
	(iii) Other financial liabilities	2,688.19	2,157.74	4,542.84	3,193.46
	(b) Other current liabilities	3,860.94	2,429.44	4,660.12	3,278.43
	(c) Provisions	313.30	302.35	1,040.81	957.79
	(d) Current tax liabilities (net)	0.66	-	215.02	18.59
	<b>Total Current Liabilities</b>	<b>61,284.89</b>	<b>60,745.87</b>	<b>85,056.70</b>	<b>73,227.48</b>
	<b>Total Liabilities</b>	<b>82,648.00</b>	<b>85,627.99</b>	<b>121,986.59</b>	<b>109,477.36</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>145,620.29</b>	<b>157,199.39</b>	<b>188,516.52</b>	<b>195,172.40</b>

For Camlin Fine Sciences Limited

*Ashish S. Dandekar*  
Ashish S. Dandekar  
Chairman & Managing Director  
DIN: 01077379



Place: Mumbai  
Date: November 11, 2024



**Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLC075361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfo.com

www.camlinfo.com

**CAMLIN FINE SCIENCES LIMITED**  
**STANDALONE STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2024**

(Rs.in Lakh)

Particulars	For half year ended September 30,2024 (Unaudited)	For half year ended September 30,2023 (Unaudited)
<b>Cash Flow from Operating Activities</b>		
(Loss) / Profit Before Tax	(12,813.26)	673.88
<b>Adjustment for:</b>		
Depreciation and Amortisation Expense	2,612.96	2,420.64
Finance Costs	3,153.49	2,714.89
Foreign Exchange Loss / (Gain) (Unrealised)	283.83	142.33
(Gain)/Loss on sale of Property, Plant & Equipment and Intangible Assets	177.35	(0.12)
Allowance/(Reversal) of Credit Loss	(33.97)	(82.96)
Allowances for Doubtful advances	-	2.12
Expense/(Reversal) recognised in respect of equity-settled share-based payments	14.27	0.15
Provision for Defined Benefit Plans	94.35	94.66
Interest Income	(245.39)	(227.14)
Interest Income on other financial assets	(13.60)	-
Guarantee Commission	(13.67)	(13.67)
Provision for impairment in the value of investments and assets	9,449.31	-
Net Gain arising on Financial Liabilities measured at Fair Value Through Profit or Loss (FVTPL)	-	(469.65)
<b>Operating Profit before working capital changes</b>	<b>2,665.67</b>	<b>5,255.13</b>
<b>Adjustment for:</b>		
Increase/(Decrease) in Non Financial Liabilities	1,395.31	(79.56)
Increase/(Decrease) in Financial Liabilities	(5,432.48)	(660.51)
(Increase)/Decrease in Non Financial Assets	(101.34)	(2,779.68)
(Increase)/Decrease in Financial Assets	3,804.14	3,793.45
<b>Cash generated from operations</b>	<b>2,331.30</b>	<b>5,528.83</b>
Taxes Paid (Net)	(82.26)	(1,040.32)
<b>Net Cash Flow from Operating activities</b>	<b>2,249.04</b>	<b>4,488.51</b>
<b>Cash Flow from Investing Activities</b>		
Purchase of Property, Plant & Equipment and Intangible Assets	(995.72)	(2,339.62)
Sale of Property, Plant & Equipment and Intangible Assets	-	7.81
Loan to Subsidiary and others	(53.48)	(193.00)
Maturity of / (Investment in) Fixed Deposit	224.33	(339.19)
Interest Received	31.32	21.95
<b>Net Cash Flow (used in) Investing Activities</b>	<b>(793.55)</b>	<b>(2,842.05)</b>
<b>Cash Flow from Financing Activities</b>		
Proceeds from Issue of Equity Shares under Employee Stock Option Plan	19.08	52.86
Proceeds from / (Repayment of) Long Term Borrowings (Net)	(1,570.43)	1,246.97
Proceeds from / (Repayment of) Short Term Borrowings (Net)	3,305.43	(1,148.63)
Payment of lease liabilities	(399.54)	(239.87)
Interest Paid	(2,854.36)	(1,978.37)
<b>Net Cash Flow used in Financing Activities</b>	<b>(1,499.82)</b>	<b>(2,067.04)</b>
<b>Net Decrease in Cash &amp; Cash Equivalents</b>	<b>(44.33)</b>	<b>(420.58)</b>
<b>Cash &amp; Cash Equivalents at the beginning of the year</b>	<b>67.70</b>	<b>435.06</b>
<b>Cash &amp; Cash Equivalents at the end of half year</b>	<b>23.37</b>	<b>14.48</b>

**Note :**

(a) The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - Statement of Cash Flows.

(b) Cash and Cash Equivalents comprises of :

Particulars	For half year ended September 30,2024 (Unaudited)	For half year ended September 30,2023 (Unaudited)
Balances with Banks in Current Accounts	21.20	11.12
Cash on Hand	2.17	3.36
<b>Cash and cash equivalents in Statement of Cash Flow</b>	<b>23.37</b>	<b>14.48</b>

FOR Camlin Fine Sciences Limited



Ashish S. Dandekar  
Chairman & Managing Director  
DIN: 01077379



Place: Mumbai

Mumbai, Dated: November 11, 2024



**Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLC075361

CAMLIN FINE SCIENCES LIMITED

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2024

(Rs in Lakh)

Particulars	For the half year ended September 30, 2024 (Unaudited)	For half year ended September 30, 2023 (Unaudited)
<b>Cash Flow from Operating Activities</b>		
(Loss) / Profit Before Tax	(16,578.77)	399.22
<b>Adjustment for:</b>		
Depreciation and amortisation expense	4,080.29	3,798.11
Finance costs	4,979.56	2,999.79
Foreign exchange loss / (gain) (unrealised)	1,793.69	1,203.88
Loss on sale/discard of Property, Plant & Equipment	293.05	(15.95)
Provision for impairment in the value of assets	14,059.83	-
Allowance / (Reversal) for Credit Loss	(33.97)	(28.11)
Allowance for Doubtful Advances	-	2.12
Expenses / (reversal) recognised in respect of equity settled share based payments	-	0.20
Provision for defined benefit plans and compensated absences	167.77	195.75
Interest income	(62.88)	(52.88)
Hyperinflationary effect on Consolidated Statement of Profit and Loss	432.42	(204.65)
Share of Profit of associate	(50.50)	-
Net gain arising on Financial Liabilities measured at Fair Value Through Profit or Loss (FVTPL)	-	(469.65)
<b>Operating Profit before working capital changes</b>	<b>9,080.49</b>	<b>7,827.83</b>
<b>Adjustment for:</b>		
Increase/(Decrease) in Non Financial Liabilities	48.00	(431.29)
Increase/(Decrease) in Financial Liabilities	(1,259.95)	(4,916.63)
(Increase)/Decrease in Non Financial Assets	(72.10)	(1,869.86)
(Increase)/Decrease in Financial Assets	461.99	5,936.12
<b>Cash generated from operations</b>	<b>8,258.43</b>	<b>6,546.17</b>
Taxes Paid (Net)	(1,698.06)	(2,175.09)
<b>Net Cash Flow from Operating activities</b>	<b>6,560.37</b>	<b>4,371.08</b>
<b>Cash Flow from Investing Activities</b>		
Purchase of Property, Plant & Equipment and Intangible Assets	(2,707.65)	(2,674.49)
Sale of Property, Plant & Equipment and Intangible Assets	-	37.31
Sale/ (Purchase) of non-current investments	-	8.30
Loans given	-	5.85
Maturity of / (Investment in) Fixed Deposit	218.32	(338.15)
Interest Received	62.88	52.88
<b>Net Cash Flows used in Investing Activities</b>	<b>(2,426.45)</b>	<b>(2,908.30)</b>
<b>Cash Flow from Financing Activities</b>		
Proceeds from Issue of Equity Shares under Employee Stock Option Scheme / Plan	19.08	52.86
Proceeds from / (Repayment of) Long Term Borrowings (Net)	(1,949.86)	1,893.40
Proceeds from / (Repayment of) Short Term Borrowings (Net)	1,530.13	(351.85)
Payment of lease liabilities	(393.34)	(469.60)
Interest Paid	(3,415.90)	(2,491.87)
Payment of preferred dividend	-	(227.73)
<b>Net Cash Flow used in Financing Activities</b>	<b>(4,209.89)</b>	<b>(1,594.79)</b>
<b>Net Decrease in Cash &amp; Cash Equivalents</b>	<b>(75.97)</b>	<b>(132.01)</b>
<b>Cash &amp; Cash Equivalents at the beginning of the year</b>	<b>8,025.47</b>	<b>9,374.24</b>
<b>Cash &amp; Cash Equivalents at the end of half year</b>	<b>7,949.50</b>	<b>9,242.23</b>

Notes:

(a) The above Consolidated Statement of Cash Flows has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - Statement of Cash Flows.

(b) Cash and Cash Equivalents comprises of :

(Rs In Lakh)

Particulars	As at	
	September 30, 2024	September 30, 2023
Balances with banks in current accounts	7,776.79	9,104.25
Cash on hand	172.71	137.98
<b>Cash and cash equivalents in Consolidated Statement of Cash Flows</b>	<b>7,949.50</b>	<b>9,242.23</b>

Place: Mumbai  
Date: November 11, 2024



FOR CAMLIN FINE SCIENCES LIMITED

Ashish S. Dandekar  
Chairman & Managing Director



Registered Office:  
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai - 400 098.  
CIN: L74100MH1993PLC075361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfo.com

www.camlinfo.com



# KALYANIWALLA & MISTRY LLP


CHARTERED ACCOUNTANTS

The Board of Directors  
Camlin Fine Sciences Limited

## LIMITED REVIEW REPORT

- 1) We have reviewed the accompanying Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2024, of **Camlin Fine Sciences Limited** ("the Company") together with the Unaudited Standalone Statement of Assets and Liabilities, Unaudited Standalone Statement of Cash Flows and the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations") duly initialled by us for identification.
- 2) This Statement, which is the responsibility of the Company's Management, has been reviewed by the Audit Committee and approved by the Board of Directors, at their respective meetings held on November 11, 2024, and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, ("the Act") read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Kalyaniwalla & Mistry LLP**  
Chartered Accountants  
Firm Registration No.: 104607W/W100166

  
Anil A. Kulkarni  
Partner  
Membership No.: 047576  
UDIN: 24047576BKBJTV5549  
Place: Mumbai  
Date: November 11, 2024



LLP IN : AAH - 3437

# KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

The Board of Directors  
Camlin Fine Sciences Limited

## LIMITED REVIEW REPORT

- 1) We have reviewed the accompanying Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2024 of **Camlin Fine Sciences Limited** ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of net profit / loss after tax and total comprehensive income of an associate company of its subsidiary company (refer paragraph 4 below) together with the Unaudited Consolidated Statement of Assets and Liabilities, Unaudited Consolidated Statement of Cash Flows and the notes thereon ("the Statement"), attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ("the Listing Regulations") duly initialed by us for identification.
- 2) This Statement, which is the responsibility of the Parent's Management has been reviewed by the Parent's Audit Committee and approved by Parent's Board of Directors, at their respective meetings held on November 11, 2024, and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, ("the Act"), read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001  
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

4) The Statement includes the results of the following entities:

**Incorporated In India**

<b>Sr. No.</b>	<b>Name of the Entity</b>	<b>Relationship</b>
i.	Chemolutions Chemicals Ltd.	Subsidiary
ii.	AlgalR Nutra Pharms Private Limited	Subsidiary

**Incorporated Outside India**

<b>Sr. No.</b>	<b>Name of the Entity</b>	<b>Relationship</b>
i.	CFS North America LLC	Wholly owned subsidiary
ii.	CFS Do Brasil Indústria, Comércio, Importação e Exportação De Aditivos Alimentícios LTDA	Wholly owned subsidiary
iii.	Solentus North America Inc	Wholly owned subsidiary
iv.	CFS Europe S.P.A	Wholly owned subsidiary
v.	Dresen Quimica S.A.P.I de C.V.	Wholly owned subsidiary
vi.	Industrias Petrotec De Mexico S.A. de C.V.	Step down subsidiary
vii.	Nuvel, S.A.C.	Step down subsidiary
viii.	Britec, S.A.	Step down subsidiary
ix.	Inovel, S.A.S	Step down subsidiary
x.	Grinel, S.R.L	Step down subsidiary
xi.	CFS Wanglong Flavors (Ningbo) Co. Ltd.	Subsidiary
xii.	CFS Pahang Asia Pte. Ltd.	Subsidiary
xiii.	CFS Argentina S.A.	Step down subsidiary
xiv.	CFS Chile De SPA	Step down subsidiary
xv.	CFS De Mexico Blends, S.A.P.I DE CV	Wholly owned subsidiary
xvi.	CFS PP (M) SDN. BHD	Subsidiary
xvii.	Vitafor Invest NV, Belgium (w.e.f. June 11, 2024)	Step down subsidiary
xviii.	Vitafor NV (w.e.f. June 11, 2024)	Step down subsidiary
xix.	Addi-Tech NV (w.e.f. June 11,2024)	Step down subsidiary
xx.	Vitafor China Ltd. (w.e.f. June 11,2024)	Step down subsidiary
xxi.	Europe Bio Engineering BV (w.e.f. June 11, 2024)	Step down subsidiary
xxii.	Vial SARL (w.e.f. June 11, 2024)	Associate Company of a Step down subsidiary



- 5) Based on our review conducted and procedures performed as stated in paragraph 3 above, and based on the consideration of the review reports of the other auditors referred to in paragraph 6(A) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6) Other Matters:
- A. We did not review the interim financial results of 16 subsidiaries incorporated outside India and 2 subsidiaries in India included in the Statement, whose interim financial results reflect Group's share of total assets of Rs. 1,24,777.48 Lakh as at September 30, 2024 and Group's share of total revenues of Rs. 29,585.43 Lakh and Rs. 57,457.14 Lakh for the quarter and for the half year ended, respectively, Group's share of total net profit / (loss) after tax of Rs. 805.37 Lakh and Rs. (706.99) Lakh and total comprehensive income of Rs. 631.82 Lakh and Rs. (1,860.73) Lakh for the quarter and half year ended September 30, 2024, respectively, and Cash flow (net inflow) of Rs. 578.93 Lakh for the half year ended September 30, 2024.

The Statement also includes the Group's share of net profit after tax and total comprehensive income of Rs. 50.50 Lakh for the quarter and half year ended September 30, 2024, as considered in the consolidated unaudited financial results, in respect of an associate of a subsidiary, located outside India.

These interim financial results of the subsidiaries and associate as mentioned in this paragraph have been reviewed by other auditors whose reports have been furnished to us by the Parent's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

In respect of these subsidiaries (including an associate) located outside India whose interim financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which has been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's Management has converted the interim financial results of these subsidiaries (including an associate) located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India (Indian Accounting Standards "Ind AS"). We have reviewed these conversion adjustments made by the Parent's Management.




**KALYANIWALLA  
& MISTRY LLP**

B. The Statement includes interim financial results of 5 subsidiaries incorporated outside India which have not been reviewed and have been included on the basis of the Unaudited Management Accounts, whose interim financial results reflect Group's share of total assets of Rs. 2,439.99 Lakh as at September 30, 2024 and Group's share of total revenues of Rs. 533.41 Lakh and Rs. 1,006.86 Lakh for the quarter and half year ended September 30, 2024, respectively, Group's share of total net profit / (loss) after tax of Rs. (448.77) Lakh and Rs. (614.55) Lakh and total comprehensive income of Rs. 7.29 Lakh and Rs. 51.12 Lakh for the quarter and half year ended September 30, 2024, respectively, and Cash flow (net outflow) of Rs. 96.01 Lakh for the half year ended September 30, 2024. These interim financial results have been furnished to us by the Parent's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on such interim financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matters.

For Kalyaniwalla & Mistry LLP  
Chartered Accountants  
Firm Registration No.: 104607W/W100166



Anil A. Kulkarni  
Partner  
Membership No.: 047576  
UDIN: 24047576BKBJTW7570  
Place: Mumbai  
Date: November 11, 2024





For Camlin Fine Sciences Limited

*Ashish S. Dandekar*  
Ashish S. Dandekar  
Chairman & Managing Director  
DIN: 01077379

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024													
(Rs.in Lakh, except per share data)													
No.	PARTICULARS	STANDALONE						CONSOLIDATED					
		QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total Income from Operations	22,691.18	18,191.22	20,621.41	40,882.40	36,732.57	77,326.21	42,297.15	39,585.33	40,587.94	81,882.48	82,548.20	161,306.20
2	Net Profit / (Loss) for the period (before tax and exceptional items)	(1,426.91)	(1,759.69)	(52.34)	(3,186.60)	673.88	(5,770.40)	822.69	(2,348.06)	(1,208.50)	(1,525.37)	399.22	(4,943.95)
3	Net Profit / (Loss) for the period before tax (after exceptional items)	(11,053.57)	(1,759.69)	(52.34)	(12,813.26)	673.88	(5,963.24)	(14,230.71)	(2,348.06)	(1,208.50)	(16,578.77)	399.22	(9,924.35)
4	Net Profit / (Loss) for the period after tax (after exceptional items)	(7,262.16)	(1,368.01)	(145.56)	(8,630.17)	432.48	(5,138.92)	(11,610.78)	(3,465.02)	(2,082.94)	(15,075.80)	(881.27)	(10,487.51)
5	Net Profit / Loss for the period after tax and non-controlling interests (after exceptional items)							(10,023.16)	(3,395.41)	(1,938.30)	(13,418.57)	(382.84)	(9,275.34)
6	Total Comprehensive Income for the period	(7,333.69)	(1,312.71)	(249.74)	(8,646.40)	459.27	(5,143.38)	(11,608.23)	(4,059.89)	(2,330.54)	(15,668.12)	(631.43)	(8,691.10)
7	Equity Share Capital	1,674.95	1,674.95	1,674.55	1,674.95	1,674.55	1,674.65	1,674.95	1,674.95	1,674.55	1,674.95	1,674.55	1,674.65
8	Other Equity				61,297.34	75,493.68	69,896.73				67,301.82	92,628.44	84,800.43
9	Earnings per share (of Re 1/-each) (not annualised)												
	-Basic Rs.	(4.34)	(0.82)	(0.09)	(5.15)	0.26	(3.09)	(5.98)	(2.03)	(1.17)	(8.01)	(0.23)	(5.58)
	-Diluted Rs.	(4.29)	(0.81)	(0.09)	(5.10)	0.26	(3.05)	(5.93)	(2.01)	(1.16)	(7.94)	(0.23)	(5.50)

1 The above information is an extract of the detailed format of unaudited results for the quarter ended September 30, 2024 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited results for the quarter September 30, 2024 are available on the Company's website at [www.camlinfs.com](http://www.camlinfs.com) and the Stock Exchange websites i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com).

Place: Mumbai  
Date: November 11, 2024

Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kailina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLC075361

+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

## Annexure 2

Sr. No.	Particulars	Details
a)	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	As on March 31, 2024 Turnover: Rs. NIL Percentage: NA Net worth: Rs. 30,63,172.78 Percentage: 0.04%
b)	Date on which the agreement for sale has been entered into	Not Applicable  The Board has approved the Liquidation of CFS Pahang Asia Pte Ltd., Subsidiary Company on November 11, 2024.
c)	The expected date of completion of sale/disposal	The Liquidation is expected to be completed by March 31, 2025.
d)	Consideration received from such sale/disposal	Repayment of proceeds of Liquidation if any, after completion of Voluntary Liquidation process.
e)	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof	Not Applicable
f)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length"	Not Applicable
g)	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale	Not Applicable



**Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLCO75361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

**Annexure 3**

<b>Particulars</b>	<b>Details</b>
<b>Name</b>	<b>Mr. Saurabh Upadhyay</b>
<b>Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise</b>	Appointment as General Manager - Food Division designated as Senior Management Personnel
<b>Date of appointment/re-appointment/cessation (as applicable) &amp; term of appointment/re-appointment</b>	Date of appointment: on or before November 28, 2024.  Terms and conditions of appointment shall be as per the existing policies of the Company.
<b>Brief profile (in case of appointment)</b>	<p>Mr. Saurabh Upadhyay has done Diploma in International Marketing from Ahmedabad Management Association, B-Tech in Food Technology from Jaipur National University. He has also done MBA/PGDM in Agri Business Management from MIT CON Institute of Management, Pune and Certification in Strategic Management from Indian Institute of Management, Rohtak.</p> <p>Mr. Saurabh Upadhyay is a dynamic and experienced professional with a career spanning approximately 10 years in the Food, Pharma, and Chemical Ingredients B2B industry, he has successfully operated in the Asia, Middle East, and Africa region. He is a skilled and adaptable professional with expertise in Food and Agriculture Business Management, coupled with a background in Food Engineering and a certification in Strategic Management. His broad skill set applies across diverse sectors and roles such as Food, Pharma, Paper, Chemical Industry, and Commodities.</p>
<b>disclosure of relationships between directors (in case of appointment of a director)</b>	Not related to any Director of the Company.



**Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLCO75361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com